Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-443-7400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.75 million
Profitability
Miscellaneous
Employees45
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable
Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions
What is Harpoon Therapeutics' stock symbol?
Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."
How were Harpoon Therapeutics' earnings last quarter?
Harpoon Therapeutics Inc (NASDAQ:HARP) announced its earnings results on Monday, August, 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.14. The company had revenue of $1.06 million for the quarter, compared to analyst estimates of $1.22 million. Harpoon Therapeutics had a negative net margin of 1,107.97% and a negative return on equity of 86.88%. View Harpoon Therapeutics' Earnings History.
When is Harpoon Therapeutics' next earnings date?
What price target have analysts set for HARP?
7 analysts have issued 1 year price targets for Harpoon Therapeutics' shares. Their forecasts range from $23.00 to $28.00. On average, they anticipate Harpoon Therapeutics' stock price to reach $25.00 in the next year. This suggests a possible upside of 70.3% from the stock's current price. View Analyst Price Targets for Harpoon Therapeutics.
What is the consensus analysts' recommendation for Harpoon Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harpoon Therapeutics.
Has Harpoon Therapeutics been receiving favorable news coverage?
News coverage about HARP stock has been trending neutral on Monday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Harpoon Therapeutics earned a news sentiment score of 0.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Harpoon Therapeutics.
Are investors shorting Harpoon Therapeutics?
Harpoon Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 329,000 shares, an increase of 32.1% from the January 15th total of 249,100 shares. Based on an average daily volume of 114,900 shares, the short-interest ratio is currently 2.9 days. Currently, 2.4% of the company's shares are short sold. View Harpoon Therapeutics' Current Options Chain.
Who are some of Harpoon Therapeutics' key competitors?
Some companies that are related to Harpoon Therapeutics include SpringWorks Therapeutics (SWTX), I-Mab (BDTX), Beam Therapeutics (BEAM), Editas Medicine (EDIT), NanoString Technologies (NSTG), Orchard Therapeutics (ORTX), BAVARIAN NORDIC/S (BVNRY), Twist Bioscience (TWST), Krystal Biotech (KRYS), Aerie Pharmaceuticals (AERI), Adverum Biotechnologies (ADVM), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), Vericel (VCEL) and Oyster Point Pharma (OYST).
What other stocks do shareholders of Harpoon Therapeutics own?
Who are Harpoon Therapeutics' key executives?
Harpoon Therapeutics' management team includes the folowing people:
- Dr. Luke B. Evnin, Chairman (Age 56)
- Dr. Gerald McMahon, Pres, CEO & Director (Age 64)
- Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 51)
- Dr. Natalie R. Sacks, Chief Medical Offer (Age 54)
- Ms. Georgia L. Erbez, Chief Financial Officer (Age 52)
When did Harpoon Therapeutics IPO?
(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.
Who are Harpoon Therapeutics' major shareholders?
Harpoon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include EcoR1 Capital LLC (3.69%), Fosun International Ltd (0.77%), State Street Corp (0.50%), Renaissance Technologies LLC (0.45%), Geode Capital Management LLC (0.35%) and CIBC World Markets Inc. (0.12%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Luke Evnin, Mark Chin, Natalie Sacks and Patrick Baeuerle. View Institutional Ownership Trends for Harpoon Therapeutics.
Which major investors are selling Harpoon Therapeutics stock?
HARP stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Fosun International Ltd and Goldman Sachs Group Inc.. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Holger Wesche, Mark Chin, Natalie Sacks and Patrick Baeuerle. View Insider Buying and Selling for Harpoon Therapeutics.
Which major investors are buying Harpoon Therapeutics stock?
HARP stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Geode Capital Management LLC, CIBC World Markets Inc., Russell Investments Group Ltd., Oxford Asset Management LLP, State Street Corp, UBS Group AG and Barclays PLC. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon and Luke Evnin. View Insider Buying and Selling for Harpoon Therapeutics.
How do I buy shares of Harpoon Therapeutics?
Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Harpoon Therapeutics' stock price today?
One share of HARP stock can currently be purchased for approximately $14.68.
How big of a company is Harpoon Therapeutics?
Harpoon Therapeutics has a market capitalization of $361.69 million and generates $4.75 million in revenue each year. The company earns $-27,370,000.00 in net income (profit) each year or ($25.65) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe.View Additional Information About Harpoon Therapeutics.
What is Harpoon Therapeutics' official website?
How can I contact Harpoon Therapeutics?
Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]
MarketBeat Community Rating for Harpoon Therapeutics (NASDAQ HARP)
MarketBeat's community ratings are surveys of what our community members think about Harpoon Therapeutics and other stocks. Vote "Outperform" if you believe HARP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HARP will underperform the S&P 500 over the long term. You may vote once every thirty days.
